Advanced Search: AML

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201011766

Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases

201606003

Improving risk assessment of AML with a precision genomic strategy to assess mutation clearance

201902007

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

202002074

AN EXPLORATORY PHASE 1B OPEN-LABEL MULTIARM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CC-90009 IN COMBINATION WITH ANTI-LEUKEMIA AGENTS IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA

202011122

A Phase 2 Trial Evaluating the Efficacy of Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

201911201

Identification of AML/MDS drug sensitization by in vivo chemotherapy administration

202009085

BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) who are Ineligible or who Refuse Intensive Chemotherapy

202104190

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies

202111071

A Phase I/II, Dose-Escalation study of MGTA-117 in patients with Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

201909142

Prognostic Significance of Serial Molecular Annotation in Secondary Acute Myeloid Leukemia (sAML) in patients treated with CPX-351